Kite Pharma Inc (NASDAQ:KITE)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a note issued to investors on Wednesday, AnalystRatings.Net reports. They currently have a $87.00 target price on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 69.43% from the company’s previous close.

Several other brokerages have also recently weighed in on KITE. Zacks Investment Research cut shares of Kite Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price objective on shares of Kite Pharma in a research note on Friday, November 13th. Goldman Sachs assumed coverage on shares of Kite Pharma in a research note on Wednesday, November 18th. They set a “buy” rating and a $111.00 price objective on the stock. FBR & Co. increased their price target on shares of Kite Pharma from $64.00 to $65.00 and gave the company a “market perform” rating in a research note on Friday, November 13th. Finally, Mizuho reissued a “positive” rating and set a $90.00 price target on shares of Kite Pharma in a research note on Friday, November 13th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Kite Pharma has a consensus rating of “Buy” and an average target price of $86.90.

In other Kite Pharma news, VP Rizwana F. Sproule sold 9,567 shares of the firm’s stock in a transaction that occurred on Tuesday, January 19th. The shares were sold at an average price of $55.49, for a total value of $530,872.83. Following the transaction, the vice president now directly owns 8,741 shares of the company’s stock, valued at $485,038.09. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Cynthia M. Butitta sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 27th. The shares were sold at an average price of $86.45, for a total transaction of $1,296,750.00. Following the completion of the transaction, the chief financial officer now directly owns 75,507 shares in the company, valued at $6,527,580.15. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of the company. Meeder Asset Management purchased a new stake in Kite Pharma during the fourth quarter valued at $259,000. Fox Run Management purchased a new stake in Kite Pharma during the fourth quarter valued at $314,000. DekaBank Deutsche Girozentrale raised its stake in Kite Pharma by 2.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 22,250 shares of the biopharmaceutical company’s stock valued at $1,393,000 after buying an additional 600 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Kite Pharma by 42.9% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the biopharmaceutical company’s stock worth $7,764,000 after buying an additional 37,800 shares during the last quarter.

Shares of Kite Pharma (NASDAQ:KITE) opened at 51.35 on Wednesday. Kite Pharma has a 52 week low of $44.01 and a 52 week high of $89.84. The firm’s market capitalization is $2.27 billion. The firm’s 50-day moving average is $59.81 and its 200 day moving average is $65.38.

Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.26. The firm had revenue of $5.10 million for the quarter, compared to the consensus estimate of $4.06 million. The firm’s revenue for the quarter was up 50900.0% compared to the same quarter last year. Equities research analysts forecast that Kite Pharma will post ($2.15) EPS for the current fiscal year.

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (NASDAQ:KITE), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.

12 Month Chart for NASDAQ:KITE

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.